times
Earlier this year, the government disposes of the rule that patients who go privately have to pay for the whole of their NHS treatment. Health Secretary Alan Johnson hopes this will calm Labour backbench criticism that allowing co-payments will create a two level NHS, where one patient receives a drug denied to someone on the same ward who cannot afford it. The Department of Health is also about to announce that it is working with drug companies to ensure fewer cancer drugs are turned down by the sharing body, the National Institute for health and Clinical Excellence. Bureaucrats are negotiating to pharmaceutical firms about cutting the price of new drugs to enable them to pass under NICE's cost effectiveness threshold. If a drug turns out to be more effective than previously thought and helps people live longer, its price could then be increased. The broadly followed new package of methods, which knocks over the ban on patients paying for drugs while accessing NHS care, is designed to clearly separate private care from that provided by the NHS. Patients wishing to pay for drugs will receive them at a "different time and in a different place" to where they go for their NHS care, today's report said. This ‘’different place’’ could be in the building of a private company or part of an NHS hospital which has been designated for private treatments. Patients will pay not only for the drug, but any cost over and above what would have been provided for on the NHS, including any scans or tests connected with the treatment, staff costs of administering the drug, follow-up care and the cost of any NHS equipment used for private purposes. Professor Mike Richards of cancer tsar gathered today's list of recommendations, which have been accepted by the Government in full.